Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
165,547,872
-
Total 13F shares
-
31,253,678
-
Share change
-
-1,718,483
-
Total reported value
-
$40,315,675
-
Put/Call ratio
-
9.9%
-
Price per share
-
$1.29
-
Number of holders
-
60
-
Value change
-
-$2,408,012
-
Number of buys
-
13
-
Number of sells
-
31
Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q3 2023
As of 30 Sep 2023 CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) had 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 31,253,678 shares of stock of the company.
Largest 10 holders included BVF INC/IL, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, Laurion Capital Management LP, JACOBS LEVY EQUITY MANAGEMENT, INC, RENAISSANCE TECHNOLOGIES LLC, Bronte Capital Management Pty Ltd., FMR LLC, and MILLENNIUM MANAGEMENT LLC.
This table shows 60 institutional shareholders of the security as of 30 Sep 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.